PRELUDE CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 129 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2017. The put-call ratio across all filers is 0.95 and the average weighting 0.8%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2017$52,000
-85.1%
18,300
+31.8%
0.01%
-89.8%
Q2 2015$350,000
-9.6%
13,8860.0%0.05%
-9.3%
Q1 2015$387,00013,8860.05%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2017
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders